Mercyone Waterloo Medical Center
- Type
- Teaching hospital
- Where
- Waterloo, IA
- Medicare CCN
- 160067
- Received
- $1,146,619 in 19 records, 2024 ($8,573 general, $1,138,046 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: MERCYONE WATERLOO MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 4 | $8,573 |
| 2024 | Research payment | 15 | $1,138,046 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Eli Lilly and Company | 6 | $747,108 | 2024 |
| CSL Behring | 6 | $382,124 | 2024 |
| Novartis Pharmaceuticals Corporation | 1 | $7,628 | 2024 |
| Stryker Corporation | 2 | $6,655 | 2024 |
| Applied Medical Resources Corporation | 1 | $1,881 | 2024 |
| Celgene Corporation | 1 | $790 | 2024 |
| E.R. Squibb & Sons, L.L.C. | 1 | $395 | 2024 |
| Siemens Medical Solutions USA, Inc. | 1 | $36 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 15 | $1,138,046 |
| Long term medical supply or device loan | 1 | $5,712 |
| Education | 1 | $1,881 |
| Debt forgiveness | 2 | $980 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Stryker Corporation | $5,712 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2024 | |
| 2024-12-31 | Stryker Corporation | $943 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $36 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | $395 | Research payment | Cash or cash equivalent | Connect MM The Multiple Myeloma Disease Registry | 2024 | |
| 2024-07-09 | CSL Behring | $3,200 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-06-28 | CSL Behring | $364,311 | Research payment | Cash or cash equivalent | Kcentra Biological, Trauma (Emergency, Injury, Surgery) | A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE111 | 2024 |
| 2024-06-03 | CSL Behring | $8,512 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-05-16 | Celgene Corporation | $790 | Research payment | Cash or cash equivalent | Connect MM- The Multiple Myeloma Disease Registry | 2024 | |
| 2024-03-15 | CSL Behring | $3,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-15 | CSL Behring | $1,600 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-15 | CSL Behring | $1,500 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-03-01 | Novartis Pharmaceuticals Corporation | $7,628 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car | 2024 |
| 2024-02-06 | Eli Lilly and Company | $225,154 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 | |
| 2024-01-29 | Applied Medical Resources Corporation | $1,881 | Education | In-kind items and services | Alexis Contained Extraction System Device, INSTRUMENTATION | 2024 | |
| 2024-01-25 | Eli Lilly and Company | $4,164 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 | |
| 2024-01-25 | Eli Lilly and Company | $4,143 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIM | 2024 | |
| 2024-01-09 | Eli Lilly and Company | $2,737 | Research payment | In-kind items and services | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 | |
| 2024-01-02 | Eli Lilly and Company | $363,933 | Research payment | Cash or cash equivalent | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2024 | |
| 2024-01-02 | Eli Lilly and Company | $146,975 | Research payment | Cash or cash equivalent | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Waterloo, IA, county Black Hawk County, IA, state Iowa; placed by its city name.
| Measure | Place (city or town) Waterloo, IA | County Black Hawk County, IA | State Iowa |
|---|---|---|---|
| Population B01003 | 67,008 | 131,049 | 3,210,507 |
| Population, 2020 census P1 | 67,314 | 131,144 | 3,190,369 |
| Median age B01002 | 36.7 | 35.7 | 38.6 |
| Under 18 B01001 | 24.5% | 21.9% | 22.9% |
| 65 and over B01001 | 17.0% | 17.7% | 18.1% |
| Households B11001 | 29,283 | 54,563 | 1,315,707 |
| Foreign born B05002 | 10.1% | 6.5% | 5.9% |
| Median household income B19013 | $57,480 | $66,417 | $75,059 |
| Median family income B19113 | $72,697 | $86,857 | $97,491 |
| Per capita income B19301 | $32,837 | $37,541 | $40,877 |
| Poverty rate B17001 | 16.6% | 14.9% | 11.1% |
| Unemployment rate B23025 | 5.3% | 4.6% | 3.6% |
| Civilian labor force B23025 | 34,281 | 70,124 | 1,699,994 |
| Mean commute (minutes) B08013 | 15.9 | 15.9 | 19.8 |
| Bachelor's degree or higher B15003 | 21.8% | 30.3% | 31.4% |
| Housing units B25001 | 32,143 | 58,991 | 1,437,699 |
| Owner-occupied B25003 | 62.1% | 66.2% | 71.7% |
| Renters B25003 | 37.9% | 33.8% | 28.3% |
| Median home value B25077 | $152,600 | $188,900 | $208,000 |
| Median gross rent B25064 | $923 | $989 | $972 |
| White, not Hispanic B03002 | 65.5% | 78.1% | 82.3% |
| Black B03002 | 16.4% | 9.1% | 3.8% |
| Hispanic or Latino B03002 | 8.4% | 5.2% | 7.3% |
| Asian B03002 | 3.2% | 2.7% | 2.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.2% |
Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Waterloo, IA.
Comments